Literature DB >> 717538

Tumor immunity. An overview.

B V Siegel.   

Abstract

The frequent failure of the host's immunologic responses to impose restraints on tumor growth and dissemination has led to the realization that a number of factors, both immunologic and nonimmunologic, may act in concert to affect tumorigenesis. Immunologic mechanisms involved in tumor cell destruction are predicated principally on in vitro procedures, but the relevancy of these experimental observations to the actual events in vivo remains unclear and unresolved. The macrophage has been shown to be an integral segment of the immune response and to constitute an important element of the host defense against tumors. In this connection, interferon may be implicated in tumor cell destruction through macrophage activation to cytotoxicity. Studies of age-related susceptibility of New Zealand Black mice to three different carcinogens, ie, 3-methylcholanthrene, x-irradiation, and murine leukemia virus, have further emphasized the multifactorial determinants which may be operational in oncogenesis. Advances in our knowledge of tumor immunology have suggested a number of possible modalities for preventing tumors from escaping immunologic destruction and should continue to contribute to further elucidation of neoplastic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 717538      PMCID: PMC2018372     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

Review 1.  Levamisole in the modulation of the immune response: the current experimental and clinical state.

Authors:  J Symoens; M Rosenthal
Journal:  J Reticuloendothel Soc       Date:  1977-03

2.  The macrophage and cancer.

Authors:  B V Siegel
Journal:  J Reticuloendothel Soc       Date:  1976-09

3.  Immunotherapy of cancer.

Authors:  H F Oettgen
Journal:  N Engl J Med       Date:  1977-09-01       Impact factor: 91.245

Review 4.  Immunostimulation of the lymphodependent phase of neoplastic growth.

Authors:  R T Prehn
Journal:  J Natl Cancer Inst       Date:  1977-10       Impact factor: 13.506

5.  Neoantigens on spontaneous and carcinogen-induced rat tumors defined by in vitro lymphocytotoxicity assays.

Authors:  R W Baldwin; M J Embleton
Journal:  Int J Cancer       Date:  1974-04-15       Impact factor: 7.396

6.  Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance.

Authors:  J B Hibbs; L H Lambert; J S Remington
Journal:  Nat New Biol       Date:  1972-01-12

7.  Endotoxin and double stranded RNA render macrophages cytotoxic.

Authors:  P Alexander; R Evans
Journal:  Nat New Biol       Date:  1971-07-21

8.  Autoimmunity and tumor resistance. 3-Methylcholanthrene tumorigenesis in New Zealand Black mice.

Authors:  J I Morton; B V Siegel; R D Moore
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

9.  Tumor virus effects on immunocyte precursor cells. Hemopoietic stem cell behavior and leukemogenic susceptibility.

Authors:  B V Siegel; J I Morton
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

10.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

View more
  3 in total

1.  In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions.

Authors:  H Maes; C Cocito
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Lymph node reactions to cancer.

Authors:  E M Meyer; E Grundmann
Journal:  Klin Wochenschr       Date:  1982-11-02

Review 3.  Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.

Authors:  Anusha Thadi; Marian Khalili; William F Morano; Scott D Richard; Steven C Katz; Wilbur B Bowne
Journal:  Vaccines (Basel)       Date:  2018-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.